Arthur Hayes Announces FLOP Testnet Launch Within Weeks 
Bank of America Predicts Yen Rebound as USD/JPY Faces Risks 
Nasdaq Faces Pullback to 26,225 Despite Bullish Outlook, UBS Says 
European Auto Stocks Rise as EU-China Trade Deal Targets Hybrid Imports 
Wall Street Ends Mixed as Investors Await CPI and Bank Earnings 
Oil Prices Fall as Trump Ceasefire Claim Shifts Market Focus to U.S. CPI 
Global Stocks Mixed as Oil Falls Ahead of US Earnings 
Russia Approves Sberbank for Crypto Exchange Services 
Trump Calls for Zelenskyy Replacement Amid Russian Diesel Deal 
Gold Prices Rebound as Dollar Weakens Ahead of US Inflation Data 
Oil Prices Rise as Houthi Attacks Threaten Middle East Supply 
US Dollar Near 18-Month High Ahead of Inflation Data 
Apple Supplier Luxshare Faces US Patent Probe, Sees Limited Impact 
US Stock Futures Rise as Oil Prices Fall Ahead of Q3 Earnings 
Airbus Tests Valkyrie Combat Drone in Europe for Eurofighter Integration 
Morgan Stanley Predicts $10 Trillion RWA Market by 2030 
TSMC Profit Set to Surge 65% as AI Chip Demand Drives Record Earnings 
Add as a preferred source on Google
Celltrion revealed on Thursday, Sept. 23, that it would be supplying its rapid COVID-19 test kit called DiaTrust to the US government. This happened after the nation’s Department of Defense awarded the contract to them.
The South Korean biopharma stated that starting October 1st, its American division, Celltrion USA, will begin delivering the DiaTrust rapid test kits to 25,000 locations. The sites include nursing homes, coronavirus testing centers, and military facilities.
According to The Korea Herald, based on the agreement signed by Celltrion and the US Defense Logistics Agency, the United States could purchase additional kits if necessary. For the initial supply, the amount of the contract is said to be $626.61 million or 738.2 billion in Korean won.
Details for the initial order, like how many would be delivered was not disclosed. However, the publication stated that Bloomberg mentioned that the deal was for a total of 19 million DiaTrust test kits. With its contract with the DOD, Celltrion became the US’ largest supplier of rapid COVID-19 test kits.
“The fact that we were awarded a procurement contract by the DLA after having passed its strict screen process is a recognition of Celltrion’s technology and supply capability,” Celltrion USA chief executive officer, Bonjoong Kim, said in a press release. “With the COVID-19 pandemic still not showing signs of waning, we plan to focus on executing this contract as diligently as possible and further solidify the external credibility of Celltrion’s diagnostic test kits portfolio.”
It was added that the DiaTrust kits that will be delivered through this deal are point-of-care tests (POCT). This means that the COVID-19 rapid test will only be used in the presence of medical professionals. Apparently, this is for safety and to ensure that the process is done properly for more accurate results.
As per Pulse News, DiaTrust was jointly developed by Celltrion and Humasis, a Korean R&D company. The test kit was authorized by the US Food and Drug Administration (FDA) for emergency use last April.
Finally, Celltrion’s DiaTrust rapid COVID-19 kit is an antigen test that is used in medical settings. It can reveal the results on the spot since it only takes as little as 15 minutes to complete.
